Prescription drug · NDA
Palsonify (Paltusotine) NDC 84015-930
Paltusotine hydrochloride 30 mg/1 · Tablet, Film coated · Oral · Crinetics Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 84015-930-60 | 84015093060 | 60 TABLET, FILM COATED in 1 BOTTLE (84015-930-60)Marketed from Sep 25, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Palsonify
- Generic name (nonproprietary)
- paltusotine
- Active ingredients
- Paltusotine hydrochloride — 30 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Crinetics Pharmaceuticals, Inc.NDC labeler code 84015
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 219070
- Marketing start
- Listing expires
- Identifiers
- Product ID 84015-930_73db4875-9ff1-4eaf-bc83-0e494aada598SPL ID 73db4875-9ff1-4eaf-bc83-0e494aada598SPL set ID 8a6d2ce0-a621-4ee7-983c-977cd948ff4dRxCUI 2724403, 2724409, 2724411, 2724413UNII FZT5Z83JNSUPC 0312345678906
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N484015093060followed by a unit qualifier and the quantityPackage 84015-0930-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option ( 1 ).
Excerpt only. Read the full label for complete information.
About NDC 84015-930
- What is NDC 84015-930?
- 84015-930 is the product NDC for Palsonify (paltusotine), Paltusotine hydrochloride 30 mg/1 tablet, film coated, listed with the FDA by Crinetics Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Palsonify (Paltusotine).
- What is the active ingredient?
- Paltusotine hydrochloride.
- Who is the labeler?
- Crinetics Pharmaceuticals, Inc., NDC labeler code 84015. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Palsonify?
- 1 other product NDC are listed under this name. See all Palsonify NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Palsonify products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Palsonifypaltusotine | Paltusotine hydrochloride 20 mg/1 | Tablet, Film coatedOral | Crinetics Pharmaceuticals, Inc. | 84015-920 | 84015-0920-60 |
Other NDCs under NDA 219070
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Palsonifypaltusotine | Paltusotine hydrochloride 20 mg/1 | Tablet, Film coatedOral | Crinetics Pharmaceuticals, Inc. | 84015-920 |